StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report sent to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of NASDAQ GLMD opened at $15.10 on Friday. The company has a market capitalization of $76.18 million, a price-to-earnings ratio of -6.29 and a beta of 0.67. The business has a 50-day moving average of $3.83 and a 200-day moving average of $4.12. Galmed Pharmaceuticals has a 1-year low of $2.73 and a 1-year high of $23.80.
About Galmed Pharmaceuticals
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.